Hyperglucagonaemia in Patients With Type 2 Diabetes - Role of Glucagon Clearance

Hyperglucagonaemia in Patients With Type 2 Diabetes - Role of Glucagon Clearance

The study aims to evaluate the elimination and degradation of glucagon in patients with type 2 diabetes compared to matched healthy subjects.

In the present project the investigators wish to identify whether the elimination and degradation of glucagon differ between healthy control subjects and patients with type 2 diabetes. Furthermore, the investigators wish to examine whether obesity is an independent factor for altered glucagon metabolism. Thus, by examining glucagon elimination in obese subjects with and without type 2 diabetes and in lean subjects with and without type 2 diabetes the investigators will be able to describe the metabolic clearance rate (MCR) of glucagon in a broad spectrum of individuals with different levels of insulin resistance and beta cell dysfunction.

Inclusion Criteria:

Patients with type 2 diabetes

• Caucasians above 35 years of age with diet or/and metformin-treated type 2 diabetes of at least 3 month duration (diagnosed according to World Health Organization (WHO) criteria
• BMI either below 27 or above 33 kg/m^2
• Normal haemoglobin
• Informed consent

Subjects with NGT

• Caucasians above 35 years of age
• BMI either below 27 or above 33 kg/m^2
• Normal HbA1c (according to WHO criteria)
• Normal haemoglobin
• Informed consent

Exclusion Criteria:

Patients with type 2 diabetes

• Inflammatory bowel disease
• Operation within the last 3 months
• Severe kidney disease (eGFR < 60 ml/min)
• Severe liver disease (serum alanine aminotransferase (ALAT) and/or serum aspartate aminotransferase (ASAT) >2×normal values)
• Pregnancy and/or breastfeeding
• Age above 80 years
• Any condition that the investigators feel would interfere with trial participation

Subjects with NGT

• Diabetes
• Prediabetes (impaired FPG or HbA1c above 42 mmol/mol)
• First-degree relatives with diabetes
• Inflammatory bowel disease
• Intestinal resection
• Severe kidney disease (eGFR < 60 ml/min)
• Liver disease (ALA T and/or serum ASA T >2×normal values)
• Pregnancy and/or breastfeeding
• Age above 80 years Any condition that the investigators feel would interfere with trial participation